Por: ABC News Business April 11, 2023
Moderna shares slipped Tuesday morning after the COVID-19 vaccine developer said its potential flu vaccine needs more study in a late-stage clinical trial.The company said an independent data and safety monitory board found that the potential vaccine “did not meet the statistical threshold necessary to declare early success” in the study.The board recommended that the trial should continue.Moderna is developing the vaccine, labeled... + full article
Portland Press Herald USA Health March 23, 2023
Moderna’s CEO on Wednesday defended a plan to more than quadruple the company’s COVID-19 vaccine price, but he also said the drugmaker will work to ensure patients continue paying nothing at drugstores or clinics. Moderna CEO Stephane Bancel testifies during the Senate HELP... + más
Moderna Stock Futures: Is COVID Vaccine Maker Moderna Poised To Pop Or Drop? | Forbes
Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate
MarketWatch USA Business February 28, 2023
The earnings announcement was a sort of rubber-hits-the-road moment for Moderna (ticker: MRNA), as investors, who have been generally anticipating a drop in Covid-19 vaccine sales ever since the jab first was authorized late 2020, for the first time could fully reckon what it... + más
Associated Press USA Health February 23, 2023
Moderna’s fourth-quarter profit tumbled 70% as COVID-19 vaccine sales fell and the drugmaker caught up on a royalty payment.Heavy research and development costs also weighed on Moderna as the vaccine developer looks to strengthen an income statement currently dominated by its... + más
MarketWatch USA Business January 18, 2023
(ticker: MRNA) said Tuesday its experimental messenger RNA-based RSV vaccine, known as mRNA-1345, was 83.7% effective at preventing less severe disease in adults aged 60 and above, and 82.4% effective at preventing more severe disease. The company only released topline results,... + más
GSK vaccine for older adults granted FDA priority review | Fox Business
Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history | CNBC
CNBC USA Health December 06, 2022
Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021.Dado Ruvic Reuters has rejected allegations made by rival that its Covid-19 vaccine is a copy, accusing the Boston biotech company of... + más
Moderna is suing Pfizer over its coronavirus vaccine | The Verge
Forbes USA Business November 29, 2022
Getty Images Key Takeaways Moderna became a household name for creating one of the first COVID-19 vaccines, helping to loosen up pandemic restrictions globally. Moderna’s stock went up during the pandemic for apparent reasons as countries were scrambling to purchase mass... + más
The Advocate USA Crime October 10, 2022
vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna’s technology in order to make their own vaccine.Moderna said Friday that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed... + más
Moderna vs Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | Los Angeles Times
About iurex | Privacy Policy | Disclaimer |